Ozmosi | Glutamine Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Glutamine

Pronounced as: gloo-tuh-meen

Alternative Names: glutamine, l-glutamine, endari, nutrestore
Clinical Status: Inactive
Latest Update: 2026-03-12
Latest Update Note: Clinical Trial Update

Product Description

Glutamine is the most abundant and versatile amino acid in the body. Glutamine is the most abundant and versatile amino acid in the body, and is of fundamental importance to intermediary metabolism, interorgan nitrogen exchange via ammonia (NH3) transport between tissues, and pH homeostasis. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266414/)

Mechanisms of Action: GLS Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral, Intravenous

FDA Designation: Orphan Drug - *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Czech | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Korea | Latvia | Lebanon | Lithuania | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Temple Therapeutics
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Gastrointestinal Cancer|Malnutrition|Enteritis|Acute Respiratory Distress Syndrome|Urinary Tract Infections|Urinary Retention|Lyme Disease|Pneumonia|Traumatic Brain Injury|Bone Marrow Transplantation|Hematopoietic Stem Cell Transplant|Anemia, Sickle Cell|Obstetric Labor, Premature|Breast Cancer|Other|Colorectal Cancer|Inflammation|Gastroenteritis|Insulin Resistance|Oxidative Stress|Mucositis|Depressive Disorder|Hypothyroidism|Stomatitis|Type 2 Diabetes|Intestinal Diseases|Cystic Fibrosis

Phase 3: Diarrhea|Kidney Diseases|Peripheral Nervous System Diseases|Vision, Low|Mucositis|Malnutrition|Surgical Wound Infection|Protein Deficiency|Weight Loss|Head and Neck Cancer|Breast Cancer|Esophagitis|Coronary Artery Disease|Breast Diseases|Inflammation|Muscular Dystrophy, Duchenne|COVID-19|Intestinal Diseases|Neck Pain|Other|Sepsis|Colorectal Cancer|Obstetric Labor, Premature|Myocardial Ischemia|Acute Kidney Injury|Heart Failure|Non-Small-Cell Lung Cancer|Respiratory Insufficiency|Pulmonary Valve Insufficiency|Overweight|Burns Unspecified|Oxidative Stress|Cachexia|Hepatitis B|Lung Injury|Weight Gain|Esophageal Cancer|Renal Cell Carcinoma|Carcinogenesis|Eye Cancer|Melanoma|Small Cell Lung Cancer|Obesity|Bone Cancer|Large Cell Carcinoma|Oncology Unspecified|Hepatitis C|Smooth Muscle Tumor|Anemia, Sickle Cell|beta-Thalassemia|Muscle Cancer|Thalassemia|Proctitis|Nose Cancer|Stomatitis|Hepatitis, Animal|Lactose Intolerance|Intestinal Cancer|NUT Carcinoma

Phase 2: Generalized anxiety disorder|Peripheral Nervous System Diseases|Endometriosis|HIV Infections|Acquired Immunodeficiency Syndrome|Other|Coronary Artery Disease|Rheumatic Heart Disease|Multiple Myeloma|Respiratory Aspiration of Gastric Contents|Muscular Dystrophy, Duchenne|Myocardial Ischemia|Mucositis|Stem Cell Transplant|Inflammation|Thalassemia|Transplantation Unspecified|Injuries/wounds Unspecified|Anemia, Sickle Cell|Breast Cancer|Communicable Diseases|Clostridium Infections|Kidney Diseases|Kidney Failure, Chronic|Insulin Resistance|Diarrhea|Colorectal Cancer|Periodontitis|Hyperglycemia|Herpes Labialis|Herpes Simplex|Irritable Bowel Syndrome|Enterocolitis, Pseudomembranous|Healthy Volunteers|Cystic Fibrosis|Kidney Cancer|Prostate Cancer|Hidradenitis Suppurativa|Ileus|Leukemia|Dyspepsia|Sarcoma|Proctitis|Lymphoma|Head and Neck Cancer|Stomatitis|Enteritis|Hypertension, Pulmonary

Phase 1: Breast Cancer|Lymphangioleiomyomatosis|Colonic Diseases|Peripheral Nervous System Diseases|Breast Diseases|Type 2 Diabetes|Crohn Disease|Diverticulosis, Colonic|Traumatic Brain Injury|Propionic Acidemia|Acidosis|Inflammation|Injuries/wounds Unspecified|Colorectal Cancer|Pancreatic Ductal Carcinoma|Head and Neck Cancer|Dermatitis, Atopic|Oncology Solid Tumor Unspecified|Squamous Cell Carcinoma|Generalized anxiety disorder|Adenocarcinoma|Pancreatic Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06291038

MISSISIIPI

N/A

Recruiting

Irritable Bowel Syndrome

2029-03-01

2026-02-21

Primary Endpoints|Start Date|Treatments|Trial Status

ChiCTR2500108082

ChiCTR2500108082

N/A

Not yet recruiting

Colorectal Cancer

2028-08-19

NCT03384108

NCT03384108

N/A

Recruiting

Healthy Volunteers

2028-01-01

2026-02-26

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

ChiCTR2500103114

ChiCTR2500103114

N/A

Not yet recruiting

Pancreatic Cancer

2027-05-20

NCT04623502

STU-2019-1061

N/A

Recruiting

Transitional Cell Carcinoma|Kidney Cancer|Papillary Adenocarcinoma|Clear Cell Adenocarcinoma|Renal Cell Carcinoma|Papillary Carcinoma|Leiomyomatosis

2027-04-30

2026-01-29

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT04785989

Chronic Lymphocytic Leukemia

N/A

Recruiting

Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

2026-10-01

2025-10-23

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT06027242

202207099RINA

N/A

Recruiting

Gastrointestinal Cancer

2026-08-30

2023-09-09

Primary Endpoints|Start Date|Treatments

NCT05972291

SPLD-006-22F

N/A

Recruiting

Irritable Bowel Syndrome

2026-07-30

2023-10-27

Primary Endpoints|Start Date|Treatments|Trial Status

NCT04883515

OBEGLUT

N/A

Recruiting

Obesity|Insulin Resistance

2026-06-01

2026-02-10

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status

ChiCTR2400082676

ChiCTR2400082676

N/A

Not yet recruiting

Heart Failure

2026-04-02

2024-04-03

Treatments

NCT06328283

Soh-Med-24-02-01MD

N/A

Not yet recruiting

Hepatocellular Carcinoma

2026-03-01

2024-03-26

Primary Endpoints|Treatments

ChiCTR2500102350

ChiCTR2500102350

N/A

Recruiting

Pulmonary Atresia|Pulmonary Heart Disease|Tetralogy of Fallot

2025-12-31

NCT07442084

SNS

N/A

Completed

Inflammation|Nose Cancer|Vascular Cancer|Inflammatory Breast Cancer|Rectal Diseases|Colorectal Cancer|Gastrointestinal Cancer|Inflammatory Bowel Diseases|Kidney Cancer|Liver Cancer|Breastfeeding|Breast Diseases|Kidney Diseases

2025-11-01

2026-03-03

Primary Endpoints

CTR20252983

CTR20252983

N/A

Completed

Duodenal Ulcer|Gastritis

2025-10-16

2025-11-09

Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

NCT07220447

NCI-2025-05686

P1

Recruiting

Oncology Solid Tumor Unspecified|Generalized anxiety disorder

2027-07-09

2026-02-13

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status

NCT03275974

NCI-2017-01543

P1

Terminated

Colorectal Cancer

2025-12-23

2026-01-03

Primary Completion Date|Primary Endpoints

2024-516595-15-00

HidraQureS/2020

P2

Not yet recruiting

Hidradenitis Suppurativa

2027-09-27

2025-05-02

Treatments

NCT04305769

ACT

P2

Recruiting

Enterocolitis, Pseudomembranous|Diarrhea|Clostridium Infections

2026-12-31

2025-08-27

Primary Endpoints|Treatments

NCT07053761

NCT07053761

P2

Not yet recruiting

Proctitis

2026-06-30

2025-07-09

Primary Endpoints

NCT07020754

FUE.REC25/8-2025

P2

Completed

Stomatitis|Head and Neck Cancer|Mucositis

2026-01-01

2026-01-31

NCT05655819

NCT05655819

P2

Completed

Dyspepsia

2025-12-31

2026-02-04

Primary Endpoints|Treatments|Trial Status

NCT06617182

KY20242229-F-1

P2

Not yet recruiting

Enteritis

2025-10-01

2024-09-28

NCT07287592

FMASU R 146/2021

P3

Not yet recruiting

Oncology Unspecified

2026-12-30

2025-12-18

Primary Endpoints|Treatments

NCT05852990

CEI/1565/21 INCAN/CEI/0074/22

P3

Recruiting

Non-Small-Cell Lung Cancer|Diarrhea

2025-12-01

2025-05-03

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT06031012

AFMMUChina-oral mucocitis

P3

Completed

Stomatitis|Mucositis

2025-10-31

2026-03-13

Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status